BACKGROUND: Circulating tumor cells (CTC) predict overall survival in patients with metastatic prostate cancer.
The objective of this study is to measure CTC before radical prostatectomy in intermediate- and high-risk prostate cancer patients.
MATERIALS AND METHODS: The study accrued 12 patients and 10 provided adequate peripheral blood sample. Blood was drawn preoperatively and assayed for CTC using the CellSearch system. Patients were categorized as CTC positive (≥ 1 CTC) or CTC negative (no CTC).
RESULTS: Median age was 64.5 years (range 49-77 years), median prostate specific antigen was 7.4 ng/ml (range 5.7-25.7 ng/ml). Seven patients had intermediate-risk and 3 patients had high-risk prostate cancer. One patient was found to be CTC positive.
CONCLUSIONS: Our pilot study shows that CTC are rare in patients with clinically localized disease despite intermediate- to high-risk features. CTC may not be the optimal marker to predict prognosis or detect residual disease after radical prostatectomy.
Written by:
Khurana KK, Grane R, Borden EC, Klein EA. Are you the author?
Glickman Urological & Kidney Institute, Cleveland, Ohio, USA; Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
Reference: Curr Urol. 2013 Nov;7(2):65-9.
doi: 10.1159/000356251
PubMed Abstract
PMID: 24917761
UroToday.com Prostate Cancer Section
